AGOVIRAXi toimeainetega seotud uuringud:
  1. SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan. Martina Morokutti-Kurz et al, 2020. BioRxiv preprint doi:
  2. Bansal et al. Iota-carrageenan and Xylitol inhibit SARS-CoV-2 in cell culture. Posted August 21, 2020. doi: bioRxiv preprint.
  3. Carvallo et al. Study of the Efficacy and Safety of Topical Ivermectine + Iota-carrageenan in the Prophylaxis Against COVID-19 in Health Personnel.Grassauer et al. Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virology Journal 2008, 5:107.
  4. Leibbrandt A et al. Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection. PLoS ONE 5(12): e14320. doi:10.1371/journal.pone.00143202.
  5. Eccles R. et al. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respiratory Research 2010, 11:108.
  6. Fazekas T. et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold BMC Complementary and Alternative Medicine 2012, 12:147.
  7. Ludwig et al.: Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trial. Respiratory Research 2013 14:124.
  8. Koenighofer et al.: Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine 2014 9:57.
  9. Eccles R. et al. Ecacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.Respiratory Research (2015) 16:121. DOI 10.1186/s12931-015-0281-8.
  10. Eccles R. Iota-Carrageenan as an Antiviral Treatment for the Common Cold. The Open Virology Journal, 2020, Volume 14.